Johnson & Johnson deal still on track after FTC (Federal Trade Commission) request:
This article was originally published in Clinica
Johnson & Johnson still expects to close its $25.4bn acquisition of Guidant during the third quarter of 2005, it said after the US Federal Trade Commission requested additional information from the companies. Close scrutiny by the FTC was expected, because J&J's Cordis unit and Guidant both make stents. Cordis sells the Cypher drug-eluting stent, and Guidant is developing a rival product. The nature of the information requested was not disclosed.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.